Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ MD-1 Monoclonal Antibody (MD113)

Rat Monoclonal Antibody
Supplier: Invitrogen™ MA140039
Description
MA1-40039 detects MD-1 from mouse samples. MA1-40039 has been successfully used in flow cytometry and functional assay applications. The MA1-40039 immunogen is mouse MD-1 extracellular protein. Endotoxin level < 24 EU/mg.
MD-1, also known as LY86, is a glycoprotein involved in innate immunity. It is a component of the RP105/MD-1 complex, which is expressed primarily in immune cells like B-cells. MD-1 is structurally similar to MD-2, sharing only 16% sequence identity, yet both are implicated in lipopolysaccharide recognition. The protein contains the ML (MD-2-related lipid-recognition) domain, which is conserved across various species and mediates diverse biological functions by interacting with specific lipids. Structurally, MD-1 is characterized by a beta-rich fold consisting of multiple strands, which is integral to its biological activities. Though MD-1 mainly associates with RP105, its role in lipid recognition suggests functional similarities with proteins such as GM2A and NPC2, implying participation in broader immune signaling pathways.
Specifications
| MD-1 | |
| Monoclonal | |
| 0.1 mg/mL | |
| PBS with 0.1% BSA and no preservative | |
| O88188 | |
| LY86 | |
| Murine MD-1 extracellular protein. | |
| 100 μg | |
| Primary | |
| Mouse | |
| Antibody | |
| IgG2b |
| Flow Cytometry, Functional Assay | |
| MD113 | |
| Unconjugated | |
| LY86 | |
| dJ80N2.1; Ly86; Ly-86; Lymphocyte antigen 86; MD1; MD-1; MD-1, RP105-associated; MMD-1; Protein MD-1; RP1-80N2.1 | |
| Rat | |
| Protein G | |
| RUO | |
| 17084 | |
| 4°C | |
| Liquid |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction